RxDoctor Payments DataLook up a doctor →

Rosalind Berry, APRN

Family · Beckley, WVNPI 1033534342

Payments from drug & device makers

$9,479in general payments, 2019–2025

Across 596 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$795
  • Pfizer$793
  • Johnson & Johnson$746
  • Ardelyx, Inc.$695
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$9,28198%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,479 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$29,520
Medicare patients
159
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide77$55,747
XifaxanRifaximin17$37,555
IbsrelaTenapanor Hcl16$26,186
Ondansetron OdtOndansetron146$4,128
Pantoprazole Sodium293$2,976
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,763
Lubiprostone11$2,563
Dicyclomine Hcl115$1,938
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,875
Omeprazole141$1,254
Sucralfate27$1,027
Esomeprazole Magnesium21$859
LoperamideLoperamide Hcl13$425
Amitriptyline Hcl31$379
Famotidine47$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,273$55,74777 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,981$37,55517 claims
Ardelyx, Inc.Ibsrela$695$26,18616 claims
Braintree Laboratories, Inc.Sutab$58$2,76317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.

Other family in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →